- Hays, Ron D;
- Tarver, Michelle E;
- Eydelman, Malvina;
- Spaeth, George L;
- Parke, David W;
- Singh, Kuldev;
- Nguyen, Don;
- Saltzmann, Robert M;
- Smith, Oluwatosin;
- Shaw, My Le;
- Rosenberg, Lisa;
- Seibold, Leo;
- Teymoorian, Savak;
- Provencher, Lorraine M;
- Bicket, Amanda K;
- Arora, Nitika;
- Junk, Anna K;
- Chaya, Craig;
- Salim, Sarwat;
- Kuo, Debbie;
- Weiner, Asher;
- Zhang, Ze;
- Rhee, Brian Francis Douglas;
- McMillan, Brian;
- Choo, Clara;
- Garris, Winston;
- Noecker, Rob;
- Fellman, Ronald;
- Caprioli, Joseph;
- Vold, Steven;
- Pasquale, Louis;
- Cui, Qi;
- Mbagwu, Michael
Purpose
To develop a patient-reported outcome measure to assess the impact of glaucoma and treatment, including minimally invasive glaucoma surgery (MIGS).Design
Observational study before and after concomitant cataract and Food and Drug Administration-approved implantable MIGS device surgery.Setting
Survey administration was on a computer, iPad, or similar device.Patient population
184 adults completed the baseline survey, 124 a survey 3 months after surgery, and 106 the 1-month test-retest reliability survey. The age range was 37 to 89 (average age = 72). Most were female (57%), non-Hispanic White (81%), and had a college degree (56%).Main outcome measures
The Glaucoma Outcomes Survey (GOS) assesses functional limitations (27 items), vision-related symptoms (7 items), psychosocial issues (7 items), and satisfaction with microinvasive glaucoma surgery (1 item). These multiple-item scales were scored on a 0 to 100 range, with a higher score indicating worse health.Results
Internal consistency reliability estimates ranged from 0.75 to 0.93, and 1-month test-retest intraclass correlations ranged from 0.83 to 0.92 for the GOS scales. Product-moment correlations among the scales ranged from 0.56 to 0.60. Improvement in visual acuity in the study eye from baseline to the 3-month follow-up was significantly related to improvements in GOS functional limitations (r = 0.18, P = .0485), vision-related symptoms (r = 0.19, P = .0386), and psychosocial concerns (r = 0.18, P = .0503). Responders to treatment ranged from 17% for vision-related symptoms to 48% for functional limitations.Conclusions
This study supports using the GOS for ophthalmic procedures such as MIGS. Further evaluation of the GOS in different patient subgroups and clinical settings is needed.